Search Results - Birgit Assmus

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design

    EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design by Matthias Paul, Ralph Bosch, Behrus Subin, Angelika Guth, Marlena Mueller, Mareike Seelinger, Stephanie Riemann, Birgit Assmus

    Published 2025-08-01

    Abstract Aims Heart failure (HF) is one of today's leading public health issues worldwide. The sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin recently received a label expansion. It is now approved for treatment of HF across the entire spectrum of ejection fraction (EF) in Germ...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    A Word of Caution—Potential Limitations of Pulmonary Artery Pressure Monitoring in Detecting Congestion Caused by Right-Sided Heart Failure

    A Word of Caution—Potential Limitations of Pulmonary Artery Pressure Monitoring in Detecting Congestion Caused by Right-Sided Heart Failure by Ester Judith Herrmann, Eva Herrmann, Khodr Tello, Kathleen Mantzsch, Meaza Tekeste, Stephan Fichtlscherer, Christian W. Hamm, Birgit Assmus

    Published 2025-06-01

    <b>Background/Objectives:</b> Patients with New York Heart Association (NYHA) class III heart failure (HF) suffer from frequent hospitalizations. Non-invasive pulmonary artery pressure (PAP) sensor-guided HF care has been shown to reduce hospitalizations. However, it is unknown whether t...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: